Does Rallies show 13F holders for DAWN?

Yes. Rallies tracks hedge fund and 13F ownership data for DAWN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is DAWN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DAWN. It does not provide personalized investment advice.

DAWN (Day One Biopharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Day One Biopharmaceuticals, Inc. Common Stock (DAWN) is a publicly traded Healthcare sector company. As of May 21, 2026, DAWN trades at $21.53 with a market cap of $2.22B and a P/E ratio of -20.70. DAWN moved +0.14% today. Year to date, DAWN is +158.15%; over the trailing twelve months it is +193.72%. Its 52-week range spans $5.64 to $21.53. Analyst consensus is buy with an average price target of $23.75. Rallies surfaces DAWN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns DAWN stock?

Hedge funds tracked by Rallies that own DAWN include Viking Global, Maverick Capital, Soros Fund, Pentwater Capital, and Panagora Asset. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Day One Biopharmaceuticals, Inc. Common Stock.

DAWN Key Metrics

Key financial metrics for DAWN
Metric	Value
Price	$21.53
Market Cap	$2.22B
P/E Ratio	-20.70
EPS	$-1.04
Dividend Yield	0.00%
52-Week High	$21.53
52-Week Low	$5.64
Volume	2.99M
Avg Volume	0
Revenue (TTM)	$158.18M
Net Income	$-107.32M
Gross Margin	0.00%

Top Hedge Funds Holding DAWN

Viking Global holds 2.56M shares of DAWN, changed +0.00% as of Sep 30, 2024.
Maverick Capital holds 2.11M shares of DAWN, changed +74.55% as of Sep 30, 2024.
Soros Fund holds 1.54M shares of DAWN, changed +0.00% as of Mar 31, 2026.
Pentwater Capital holds 800.00K shares of DAWN, changed +0.00% as of Mar 31, 2026.
Panagora Asset holds 18.56K shares of DAWN, changed +0.00% as of Mar 31, 2024.

Latest DAWN News

Day One Biopharma Faces Fiduciary Probe Over $21.50 Per Share Servier Sale — Apr 9, 2026
Day One Biopharma Guides to $225M-$250M in 2026 on $155M 2025 Revenue — Mar 9, 2026
Day One Biopharmaceuticals to Merge for $2.5 Billion at $21.50 Share Price — Mar 7, 2026
Day One Biopharmaceuticals Posts Narrower $0.20 Loss, 11.4% Q4 Revenue Beat — Feb 25, 2026
Day One Shares Jump 26.7% as OJEMDA Treats 1,000+ Children, Yet Estimates Cut — Jan 13, 2026

Recent DAWN Insider Trades

Merendino Lauren sold 5.81K (~$67.45K) on Feb 17, 2026.
Dubow Adam sold 6.39K (~$74.19K) on Feb 17, 2026.
York Charles N II sold 6.07K (~$70.36K) on Feb 17, 2026.

DAWN Analyst Consensus

12 analysts cover DAWN: 0 strong buy, 6 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $23.75.

Common questions about DAWN

Who owns DAWN stock?: Hedge funds tracked by Rallies that own DAWN include Viking Global, Maverick Capital, Soros Fund, Pentwater Capital, and Panagora Asset. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Day One Biopharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for DAWN?: Yes. Rallies tracks hedge fund and 13F ownership data for DAWN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is DAWN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DAWN. It does not provide personalized investment advice.